UB Paderborn / Katalog / Suche / in CDI

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

Journal of clinical oncology, 2018-02, Vol.36 (6), p.536-542

2018

Volltextzugriff (PDF)

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

The lancet oncology, 2019-04, Vol.20 (4), p.518-530

2019

Volltextzugriff (PDF)

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

The lancet oncology, 2021-09, Vol.22 (9), p.1290-1300

2021

Volltextzugriff (PDF)

Environmental impact improvements due to introducing automation into underground copper mines

International journal of mining science and technology, 2021-11, Vol.31 (6), p.1159-1167

2021

Volltextzugriff (PDF)

Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer

Nature communications, 2018-11, Vol.9 (1), p.4850-2, Article 4850

2018

Volltextzugriff (PDF)

Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.402-402

2017

Volltextzugriff (PDF)

Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.676-676

2017

Volltextzugriff (PDF)

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

NPJ breast cancer, 2022-02, Vol.8 (1), p.18-18, Article 18

2022

Volltextzugriff (PDF)

Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2 mut MBC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.516-516

2016

Volltextzugriff (PDF)

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance

The New England journal of medicine, 2021-09, Vol.385 (13), p.1241-1243

2021

Volltextzugriff (PDF)

Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance

Cancer research (Chicago, Ill.), 2023-09, Vol.83 (17), p.2839-2857

2023

Volltextzugriff (PDF)

Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor

The journal of physical chemistry letters, 2020-12, Vol.11 (23), p.10037-10044

2020

Volltextzugriff (PDF)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Breast cancer research and treatment, 2021-05, Vol.187 (1), p.155-165

2021

Volltextzugriff (PDF)

MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3004-3004

2021

Volltextzugriff (PDF)

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Clinical cancer research, 2023-08, Vol.29 (16), p.3092-3100

2023

Volltextzugriff (PDF)

Abstract PS13-20: Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS13-20-PS13-20

2021

Volltextzugriff (PDF)

Abstract PS2-18: Circulating tumor DNA (ctDNA) mutation (mut) profile in relation to paboclicib (pal) efficacy in hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS2-18-PS2-18

2021

Volltextzugriff (PDF)

Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS4-13-PS4-13

2021

Volltextzugriff (PDF)

Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS9-02-PS9-02

2021

Volltextzugriff (PDF)

Abstract PD13-09: Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD13-09-PD13-09

2021

Volltextzugriff (PDF)

Abstract PS2-09: Next generation sequencing (NGS) in older adults with breast cancer using tissue-based and circulating tumor DNA (ctDNA) assays

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS2-09-PS2-09

2021

Volltextzugriff (PDF)

Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2 -mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1028-1028

2022

Volltextzugriff (PDF)

Abstract P2-23-10: Gene expression and mutation profiles in HER2-mutated metastatic breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P2-P2-23-10

2023

Volltextzugriff (PDF)

Abstract 4527: Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4527-4527

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Environmental impact improvements due to introducing automation into underground copper mines

Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer

Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway

Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2 mut MBC)

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance

Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Abstract PS13-20: Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

Abstract PS2-18: Circulating tumor DNA (ctDNA) mutation (mut) profile in relation to paboclicib (pal) efficacy in hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)

Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan

Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

Abstract PD13-09: Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial

Abstract PS2-09: Next generation sequencing (NGS) in older adults with breast cancer using tissue-based and circulating tumor DNA (ctDNA) assays

Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2 -mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial

Abstract P2-23-10: Gene expression and mutation profiles in HER2-mutated metastatic breast cancer

Abstract 4527: Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer

Aktive Filter

Suchergebnisse filtern